MindRank AI raised a $52 million Series B to advance MDR-001, an AI-discovered oral GLP-1 receptor agonist in phase III development in China for obesity. The company said the round will support scaling its Molecule Arts Platform and pushing forward its clinical and preclinical pipeline across multiple programs, framed as validation of its AI-first approach. Separately, digital health continues to attract capital, with Rock Health reporting $7.4 billion in venture funding in the first half of 2026, a notable year-over-year increase that signals investor appetite for software-enabled healthcare—although startup-level dispersion remains a key concern for smaller companies.